Pilbara Minerals Limited

PLS

Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 877 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australia’s resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.

Fortescue Ltd

FMG

Fortescue Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia. The firm's segments include Metals and Energy. Metals segment includes exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. Its metals business comprises its iron ore operations in the Pilbara as well as a pipeline of exploration projects globally including in Gabon in Africa, Latin America and Australia. The firm's metals business includes Hedland operations, Chichester Hub, Western Hub, Iron Bridge, Green Metal Project, integrated operations, Belinga Project, Blacksmith Project and Pilbara Energy Connect (PEC) project. Energy segment undertakes activities in the global development of green electricity, green hydrogen, green ammonia projects, as well as green technology development and manufacturing. Its energy business includes Arizona Hydrogen project, Holmaneset project, Pecem project and Gladstone PEM50 Project.

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Cogstate Ltd

CGS

Cogstate Ltd. is a global cognitive science company, which engages in delivering software services to optimize the measurement of cognition in clinical trials, academic research, healthcare and brain injury. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-02-13. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.

Core Lithium Ltd

CXO

Core Lithium Ltd. is a hard-rock lithium mining company. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.